A Tale Of Two Advisory Panels: The Divergent Fates Of Pretomanid And Plazomicin

 
• By Michael Cipriano
  
view of three wooden directional signs on a pole - Image
Panelists went in different directions when voting on approval for the two drugs.

More from US FDA Performance Tracker

More from Regulatory Trackers